Latest News Feed
Total revenue increased 60% year over year to $6.4 million
Net loss per share decreased 88% compared to the prior-year quarter
Gross margin expanded to 40% as operating expenses remained stable
FDA clearance and new global distributors support continued commercial growth
Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025
United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025
Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025
EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025
Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior year
Net loss and net loss per share decreased from prior year for both the three months and nine months ended December 31, 2025
EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025 compared to prior year
Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year
U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year
Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year
Revenues increased 18% compared to same period last year
U.S. revenue increased 57% compared to same period last year
Net loss per share decreased 43% compared to same period last year
Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024
Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024
EBITDA loss improved 59% in Q4 2025 compared to Q4 2024, and 17% in FY 2025 compared to FY 2024
Revenues increased 14% for the quarter compared to prior year and 13% year-to-date
Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024
Year-to-date net loss decline of $1.1 million
Revenue increased 31% for the quarter compared to same period prior year
Positive cash flows from operations of $0.35 million for the quarter
Net loss improved 59% for the quarter compared to same period prior year
Net loss per share improved 90% for the quarter compared to same period prior year
European revenues increased 20% compared to same period last year
Gross margin of 39% compared to 35% in same period last year
Net loss improved 19% compared to same period last year